Taub Rebecca
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to Taub Rebecca. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| MDGL | Sale | 369 | $548.56 | $202,419 | Dec 10, 2025 | |
| MDGL | Sale | 6,541 | $358.81 | $2,346,976 | Aug 11, 2025 | |
| MDGL | Option Exercise | 1,000 | $9.45 | $9,450 | Jul 18, 2025 | |
| MDGL | Sale | 1,380 | $356.52 | $491,998 | Jul 16, 2025 | |
| MDGL | Pres., R&D, and CMO | Award / Grant | 4,382 | — | — | Mar 5, 2025 |
| MDGL | Pres., R&D, and CMO | Sale | 648 | $335.24 | $217,236 | Jan 24, 2025 |
| MDGL | Pres., R&D, and CMO | Sale | 1,689 | $273.41 | $461,789 | Jan 17, 2025 |
| MDGL | Pres., R&D, and CMO | Sale | 200 | $248.58 | $49,716 | Apr 8, 2024 |
| MDGL | Pres., R&D, and CMO | Sale | 700 | $241.14 | $168,798 | Apr 5, 2024 |
| MDGL | Pres., R&D, and CMO | Award / Grant | 5,786 | — | — | Jan 23, 2024 |
| MDGL | Pres., R&D, and CMO | Tax Withholding | 1,546 | $243.92 | $377,100 | Jan 16, 2024 |
| MDGL | Pres., R&D, and CMO | Award / Grant | 20,001 | — | — | Jan 16, 2023 |
| MDGL | Chief Medical Officer, EVP R&D | Sale | 73,526 | $287.46 | $21,135,784 | Jun 11, 2018 |
| MDGL | Chief Medical Officer, EVP R&D | Award / Grant | 30,626 | — | — | Jul 22, 2016 |
| MDGL | Chief Medical Officer, EVP R&D | Award / Grant | 28,740 | — | — | Jul 22, 2016 |
| 0001003929 | SVP, Research & Development | Purchase | 32,500 | $0.30 | $9,750 | Dec 17, 2008 |